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Abstract: The (3+2) cycloaddition between azomethine ylides
and alkenes is an efficient, convergent and stereocontrolled
method for the synthesis of unnatural pyrrolidine and proline
scaffolds. In this review, the application of this reaction to the
synthesis of enantiopure organometallic ligands for asymmetric
catalysis is presented first. These new EhuPhos ligands can par-
ticipate in a second generation of 1,3-dipolar reactions that
generate an offspring of unnatural proline derivatives that be-
1. Introduction
1,3-Dipolar reactions are (3+2) cycloadditions that generate
five-membered rings in a single preparative step.[1] In many
cases, the reaction takes place with high or even complete re-
gio-, diastereo- and enantiocontrol. Among the different dipole/
dipolarophile combinations,[2] the 1,3-dipolar reaction between
azomethine ylides 1 and alkenes 2 constitutes a very efficient
and convergent method for the synthesis of pyrrolidines 3
(Scheme 1).[3] Given the fleeting nature of azomethine ylides,
the rationalization of the different outcomes and the nature of
the reaction mechanisms requires state-of-the-art computa-
tional tools, thus providing a very fruitful interplay between
theory and experiment.[4] When the azomethine ylide is stabi-
lized by an alkoxycarbonyl group the corresponding (3+2)
cycloadduct is a proline scaffold 4 that can incorporate many
different groups, thus permitting the synthesis of densely sub-
stituted and functionalized unnatural proline derivatives.
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have as efficient organocatalysts. These densely substituted un-
natural L-proline derivatives exhibit distinct features, different to
those described for natural L-proline and its derivatives. Finally,
several examples of biologically active proline derivatives ob-
tained by means of (3+2) cycloadditions involving azomethine
ylides are presented. These applications show the character of
privileged structures of these polysubstituted pyrrolidine rings.
Although the 1,3-dipolar reaction depicted in Scheme 1 is
formally a (3+2) cycloaddition, the actual mechanism can vary
from a concerted (but not necessarily synchronous) [π4s+π2s]
mechanism via supra-supra[5] transition structures TScn to a
stepwise process (Scheme 2).[6] This latter mechanism takes
Scheme 1. Synthesis of pyrrolidines 3 and, in particular, densely substituted
prolines 4 by formal (3+2) cycloaddition between azomethine ylides 1 and
alkenes 2.
Scheme 2. Alternative concerted (not necessarily synchronous) and stepwise
mechanisms in the 1,3-dipolar reaction between stabilized NH- or N-metal-
lated azomethine ylides (5a and 5b, respectively) and alkenes 2.
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place via a Michael/Mannich sequence and involves zwitterionic
intermediates 6 that in some cases can be detected.[7] There-
fore, this reaction does not follow a general mechanism and
different reaction paths can be observed depending upon the
substituents and the reaction conditions. In particular, N-metal-
lated azomethine ylides 5b (Scheme 2) in the presence of polar-
ized π-deficient alkenes 2 follow stepwise reaction paths. How-
ever, as it will be discussed below, this non-concerted mecha-
nism is compatible with an exquisite regio-, diastereo- an enan-
tiocontrol.
Stabilized azomethine ylides 9 can be generated by thermal
isomerization[8] or by metal-assisted deprotonation[9] of imines
8. Other methods such as electrocyclic ring opening of azir-
idines are also available.[10] However, the metallic salt/base
method possesses the advantage of allowing the development
of a catalytic cycle that minimizes the introduction of additional
reactants in the reaction medium. Although when doubly acti-
vated alkenes such as maleimides usually lead to concerted
mechanisms, in the case of monoactivated dipolarophiles 10
the catalytic cycle leads to a N-metallated zwitterionic interme-
diate 11 via a Michael-like nucleophilic attack of 1,3-dipole 9,
which behaves as an enolate. Intramolecular Mannich-like cycli-
zation of this intermediate gives rise to the corresponding N-
metallated pyrrolidine 12. This latter polycyclic intermediate
has a considerable strain that promotes the release of the cata-
lyst and the formation of the substituted proline ester 13
(Scheme 3).
Another advantage of the catalytic methodology depicted in
Scheme 3 is that, in the presence of chiral ligands, the N-metal-
lated azomethine ylide 9 only accepts the dipolarophile by the
less hindered prochiral face, thus allowing the formation of
Michael adducts 11 in which two chiral centers are generated
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Scheme 3. Catalytic cycle of a stepwise 1,3-dipolar reaction between imines
8 mediated by N-metallated azomethine ylides 9. EWG stands for an electron-
withdrawing group. MX is a metallic salt where M usually is CuI, CuII or AgI
and the base B is a tertiary amine. The origin of the possible enantiocontrol
by using chiral ligands in 9 is highlighted.
with high or even complete regio- and stereocontrol. From
these intermediates the ring closure gives rise to the two re-
maining chiral centers, also with very high stereocontrol. There-
fore, the highly restricted structure of intermediates 9 relies on
the nature of the chiral ligands L* (Scheme 3), which are ulti-
mately responsible for the final enantiocontrol.
2. Synthesis of Catalysts by Means of 1,3-
Dipolar Reactions
In this section the synthesis of L* ligands shown in Scheme 2 by
(3+2) cycloaddition reactions between azomethine ylides and
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alkenes will be discussed. Next, second-generation (3+2) cyclo-
additions catalyzed by these ligands will be presented and dis-
cussed. Finally, the organocatalytic activity of the (3+2) cyclo-
adducts formed in the latter process will be shown.
2.1. Ferrocenyl Prolines as Enantiopure Ligands
The activated azomethine ylides 9 shown in Scheme 3 require
a rigid environment around the 1,3-dipole to promote the pref-
erential approach of the dipolarophile along the less hindered
prochiral face. This conformationally restricted environment can
be achieved by means of chiral ligands possessing donor atoms.
Among the different possibilities, enantiopure ligands bearing
phosphine and amine functional groups (P,N-ligands)[11] consti-
tute the most efficient L* groups that can promote asymmetric
catalytic (3+2) cycloadditions between azomethine ylides and
alkenes. Within this context, ferrocenylphosphine groups incor-
porating five-membered nitrogen-containing heterocycles are
especially relevant because of the interplay between the planar
chirality of the ferrocenyl moiety and the central chirality of the
heterocycle. These ferrocenylphosphine ligands include tri-
azoles 14,[12] 1H-pyrazoles 15,[13] 1H-imidazoles 16,[14] oxazol-
ines 17[7b,7f,15] and pyrrolidines 18[16] (Figure 1). Other families
of P,N-ligands combining different kinds of chirality have been
described, including spiro polycyclic systems and axially chiral
aminophosphines.[11] However, ferrocenylphosphine ligands
benefit from a unique combination of the bulky organometallic
group, the already mentioned interplay between central and
planar chiralities and, last but not least, a robust chemistry that
permits the synthesis of different families of ligands.
Figure 1. Different chiral ferrocenyl phosphines containing five-membered
nitrogen heterocycles.
We reasoned that ferrocenylphosphino pyrrolidines bearing
four chiral centers after (3+2) cycloadditions could constitute
promising P,N-ligands[11] in which the high density of chiral cen-
ters would in turn catalyze with high stereocontrol other (3+2)
cycloadditions between azomethine ylides and nitroalkenes.
The synthesis of these P,N-ligands started with enantiomerically
pure ferrocenyl carboxaldehyde 19 prepared according the
method described by Kagan et al.[17] (Scheme 4). Direct three-
component reaction between 19, sarcosine methyl ester hydro-
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chloride 20 and (E)--nitrostyrene 21 yielded ligand NMe-L-Ehu-
Phos 22 as the sole cycloadduct. Alternatively, imine 24 was
formed from 19 and methyl glycinate hydrochloride 23. Subse-
quent (3+2) cycloaddition of 24 with dipolarophile 21 yielded
cycloadduct NH-D-EhuPhos 25 in the presence of LiBr and tri-
ethylamine (Scheme 4).[18]
Scheme 4. Synthesis of EhuPhos ligands 22 and 25.
The structures of both ligands were confirmed by X-ray dif-
fraction (Figure 2). It is noteworthy that both procedures
yielded unnatural L- and D-proline scaffolds, being the configu-
rations of the remaining chiral centers identical. It is noteworthy
that both ligands are stable and can be prepared in just one or
two preparative steps at multigram scale from readily available
materials.
Figure 2. X ray diagrams (50 % probability) of ligands 22 (NMe-L-EhuPhos,
CCDC 830011) and 25 (NH-D-EhuPhos, CCDC 830012). The different chirality
descriptors are indicated. Crystal structure of 22 corresponds to the corre-
sponding phosphine oxide. The L and D configurations of the respective
proline moieties are highlighted. The macroscopic shape of a sample of 25
is also shown.
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The behavior of these new ligands was tested in (3+2) cyclo-
additions between π-deficient alkenes and N-metallated azo-
methine ylides obtained in situ from the corresponding imines
(Scheme 5).[18] Among other results, it was observed that CuI-
N-metallated azomethine ylides coordinated to NMe-L-EhuPhos
ligand 22 produce endo-L-cycloadducts 28 with good yields
and excellent ee's (Scheme 5), whereas the corresponding exo-
L-pyrrolidines were obtained, also with excellent yields and en-
antiocontrol, in the presence of NH-D-EhuPhos ligand 25. It is
noteworthy that, considering the proline motif transmitted
from EhuPhos ligands to cycloadducts 28, the D-proline moiety
of the ligand generates an offspring of L-proline derivatives exo-
L-28, whereas the L-proline motif present in NMe-L-EhuPhos 22
is transmitted with retention of L-configuration to the endo-L-
28 offspring. In addition, neither ligand 22 nor 25 were able to
catalyze the formation of EhuPhos ligands. Therefore, the (3+2)
processes gathered in Scheme 4 cannot be made autocatalytic.
Scheme 5. (3+2) Cycloaddition reaction between nitroalkenes 26 and imines
27 catalysed by EhuPhos ligands 22 and 25. The retention or inversion of
configuration of the proline moieties in the ligands and cycloadducts are
highlighted.
Computational studies[18] on the origins of the distinct be-
havior of both ligands revealed transition structures closely re-
lated to the shape of azomethine ylides 9 (see Figure 3 and
Scheme 3). However, in the case of NMe-L-EhuPhos 22 the CuI
center cannot bind the nitrogen atom of the pyrrolidine moiety
and therefore there is a vacant in the metallic center that can
be filled by the nitro group of the alkene, thus giving rise to
the corresponding endo-cycloadduct 28. In contrast, NH-D-Ehu-
Phos 25 behaves as a true N,P-ligand and the nitro group of
nitroalkene 26 can occupy the exo position to yield the corre-
sponding exo-cycloadduct. These calculations also provided a
rationale for the enantioselectivity of the reaction. Thus, since
both ligands 22 and 25 block the same prochiral (2Re, 5Si) face
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of the azomethine ylide, only the L-configuration can be ob-
tained in the corresponding cycloadduct 28.
Figure 3. Transition structures endo-TS1 and exo-TS1 leading to (3+2) cyclo-
adducts endo-28aa and exo-28aa, respectively, catalysed by EhuPhos ligands
22 and 25. The L-shaped geometry of both ligands is highlighted (see
Scheme 3). Both structures have been computed at the B3LYP/6-31G(d)&
LANL2DZ:PM8 level of theory. Bond lengths are given in Å. This Figure was
made using Cartesian coordinates reported in ref.[18].
NMe-L-EhuPhos ligand 22 was also used by Martin et al.[19] in
the diastereo- and enantioselective (3+2) cycloaddition be-
tween C60 and N-metallated azomethine ylides derived from
imines 29a–f. Also in this case, the L-catalyst yields L-cyclo-
adducts (Scheme 6) with good chemical yields and excellent
stereocontrol. It is interesting to note that in this series of exper-
iments chiral quaternary centers at the α-position of the unnat-
ural proline ring could be generated with excellent enantiocon-
trol.
DFT calculations[19] showed that the blockade of the (2Re,
5Re) prochiral side of the azomethine ylide is associated with
the preferred conformation of ligand 22, whose rigidity stems
from the interaction of the phosphine moiety and the methoxy-
carbonyl group of the proline moiety with the CuI metallic cen-
ter. Therefore, in this case NMe-L-EhuPhos 22 behaves as a P,O-
ligand, which interacts with the azomethine ylide but not with
the dipolarophile C60. This interaction model is compatible with
the high enantioselectivity observed, since transition structure
(2S, 5S)-TS2 (Figure 4) leading to the experimentally observed
major cycloadducts (2S, 5S)-30-af, is predicted to be 3–8 kcal/
mol less energetic than the alternative (2R, 5R) saddle point.
In the preceding examples, DFT calculations showed highly
asynchronous and stepwise reaction paths. Actually, in the reac-
tion between imines and nitroalkenes in the presence of CuI
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Scheme 6. (3+2) Cycloaddition between C60 and imines 29 in the presence
of NMe-L-EhuPhos ligand 22. The retention of configuration of the L-proline
scaffold in the ligand and cycloadduct is highlighted.
Figure 4. Transition structure (2S,5S)-TS2, calculated at the M06/LANL2DZ//
B3LYP/LANL2DZ:PM6 level, associated with the formation of (2S,5S) cycload-
ducts 30 (see Scheme 6), in the presence of NMe-L-EhuPhos ligand 22. Bond
lengths are given in Å. This Figure was generated using Cartesian coordinates
reported in ref.[19].
salts (Scheme 5), the reaction takes place via zwitterionic inter-
mediates of type 11 (Scheme 3). We reasoned that substituents
that stabilize positive charges on the iminium moieties of these
intermediates could frustrate the completion of the second step
of the (3+2) cycloaddition, thus permitting the chemical synthe-
sis of γ-nitro-α-amino esters and their derivatives. In effect, we
found[20] that in the presence of 1 equiv. of NH-D-EhuPhos 25
and at –60 °C, reaction of nitroalkenes with imines 27 derived
from 4-methoxybenzaldehyde permitted to isolate syn-γ-nitro-
α-amino esters 31 with excellent enantiocontrol (Scheme 7).
Therefore, a simple electron donating group is enough to frus-
trate the (3+2) cycloaddition by stopping the stepwise process
at the Michael-like addition step. Alternatively, an additional
phenyl group present in imines 31 derived from acetophenone
is able to frustrate the cycloaddition but, in this case, only anti-
γ-nitro-α-amino esters 32 were obtained in the presence of the
same chiral ligand NH-D-EhuPhos 25 (Scheme 7). Also in this
case, DFT calculations permitted to rationalize these different
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stereochemical outcomes.[20] It is also noteworthy that, once
again, NH-D-EhuPhos, an unnatural D-Proline ester, promoted
the formation of L-amino esters via these frustrated (3+2) cyclo-
additions.
Scheme 7. Synthesis of syn- and anti-γ-nitro-α-amino esters 32 via frustrated
1,3-dipolar reaction between nitroalkenes 26 and amines 27, 31 with stoichi-
ometric amounts of NH-D-EhuPhos ligands 25. The D and L configurations of
ligand and products are highlighted.
In summary, L- and D-proline-based EhuPhos catalysts 22 and
25 are able to promote a second generation of unnatural pro-
line derivatives via (3+2) cycloadditions. This process is compat-
ible with many dipolarophiles including fullerenes. In addition,
the stepwise nature of the associated mechanism permits the
synthesis of other α-L-amino acid derivatives. It is expected that
the catalytic scope of ligands 22 and 25 will be extended to
other metal-assisted reactions.
2.2. Densely Substituted Prolines as Organocatalysts
Natural L-Proline and its derivatives constitute a privileged
structure in the field of organocatalysis.[21] However, most of
these organocatalysts are based on naturally occurring proline
or its post-translational derivatives such as L-4-hydroxyproline
or 4-L-aminoproline.[22] We reasoned that densely substituted
proline derivatives such (3+2) cycloadducts 28 described in the
preceding section could exhibit organocatalytic properties and,
even more interestingly, could provide new outcomes not ac-
cessible to organocatalysts generated from the naturally occur-
ring amino acid.
The aldol reaction was explored first.[23] Unnatural 4-nitro-L-
prolines 28 in their endo- and exo-forms were tested in the
aldol reaction between cyclic ketones 33 and aromatic alde-
hydes 34 (Scheme 8).[18,23] It was found that both L-derivatives
yielded opposite enantiomers. Thus, endo-28aa yielded
(2S,1′R)-35 aldols, the same chiral induction generated by natu-
ral L-Pro and its derivatives. In contrast, exo-28aa gave rise to
aldols possessing the (2R,1′S) stereochemistry. Therefore, since
both unnatural organocatalysts 28 have L-configuration, the
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stereochemistry of the distal positions with respect to the NH
active site is responsible for the opposite enantioselectivities
observed in these aldol reactions.
Scheme 8. Aldol reactions between cyclic ketones 33 and aldehydes 34 cata-
lysed by unnatural proline esters exo-L-28aa and endo-L-28aa. The different
stereochemical outcomes generated by the distal substituents of the L-cyclo-
adducts 28 are highlighted.
DFT calculations showed that the stereochemical outcome
of the aldol reactions gathered in Scheme 8 is determined by
the equatorial/axial/isoclinal disposition of the four substituents
of cycloadducts 28. As it can be seen by inspection of Figure 5,
both minimum energy transition structures (2R,1′S)-exo-TS3
and (2S,1′R)-endo-TS3 adopt conformations of the organocata-
lysts that maximize the number of equatorial groups. In the
case of (2R,1′S)-exo-TS3, the aryl group of the aldehyde adopts
a distal disposition with respect to the 5-phenyl group of the
organocatalyst, whereas in the case of (2S,1′R)-endo-TS3 this
disposition is proximal. The relative energies emerged from
these geometric features are in good agreement with the ob-
served enantioselectivities (Figure 5).
When different substitution patterns were analyzed, it was
observed that cis-substituents at C3,C4 resulted in much less
active organocatalysts than their C3,C4-trans congeners (Fig-
ure 6). In addition, quaternary centers at C2 were found to be
not convenient to generate good organocatalytic activity. These
results can be rationalized in terms of the number of axial cen-
ters at the C2, C3 and C4 positions of the organocatalysts, since
3,4-cis pyrrolidine scaffolds and C2 quaternized unnatural pro-
lines must necessarily include axial substituents at the corre-
sponding transition structures, thus raising the corresponding
activation energies.
Despite their ability to catalyze aldol reactions, 4-nitropro-
lines 28 resulted to be unable to catalyze Michael additions of
ketones and nitroalkenes. Instead of the expected conjugate
addition, it was found that in the presence of equimolar
amounts of acidic additives, a novel three-component reaction
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Figure 5. Optimized structures [M06–2X(PCM)/6-31G(d,p)//B3LYP(PCM)/6-
31G(d) level of theory] of transition structures (2R,1′S)-exo-TS3 and (2S,1′R)-
endo-TS3 leading to aldol adducts (2R,1′S)-35aa and (2S,1′R)-35aa, respec-
tively. Numbers in parentheses correspond to the relative energies (in kcal/
mol) of the transition structures leading to the respective stereoisomers.
Bond lengths and angles are given in Å and deg, respectively. Cartesian coor-
dinates were taken from ref.[23].
Figure 6. Effects of the substituents on the organocatalytic aldol activity of
unnatural prolines 28.
was produced.[24] This reaction, efficiently catalyzed by exo-
28aa, consists of the synthesis of 7a-hydroxyoctahydro-2H-
indol-2ones 37 from ketones 33, acids 36 and nitroalkenes 26
(Scheme 9). This unexpected addition-cyclization process in-
volves the generation of three new chiral centers in one prepar-
ative step. In addition, it tolerates different heteroatoms at the
starting ketone, as well as many substituents at the carboxylic
acid and nitroalkene moieties.
Detailed experimental and computational work led to the
catalytic cycle outlined in Figure 7A. After initial enamine forma-
tion and conjugate addition mediated by TS4 (Figure 7B), the
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Scheme 9. Three-component reaction between ketones 33, acids 36 and
nitroalkenes 26 to yield 7a-hydrroxyoctahydro-2H-indol-2-ones 37, catalyzed
by unnatural proline ester exo-28aa.
key steps include an addition of the acid or the nitronate inter-
mediate via saddle point TS5 (Figure 7C) and a rearrangement
to generate the carboxamide moiety before the cyclization step.
As far as the origins of the chiral induction of exo-L-28aa are
concerned, transition structure TS4, whose chief geometric fea-
tures are gathered in Figure 7B, shows a very efficient blockage
of one prochiral face of the nitroalkene, thus generating the
final bicyclic compound with virtually complete stereocontrol.
The potential of this reaction was exemplified by its applica-
tion to a concise synthesis of (+)-pancracine.[24,25] In this synthe-
sis, adduct 37n was obtained from readily available reactants
33f and 26h in satisfactory yield and virtually complete ee, de-
spite working at a relatively high reaction temperature. It is
interesting to note that nearly all the chiral information present
in the alkaloid is generated in a single preparative step leading
to adduct 37n (Scheme 10).[24]
Although 4-nitroprolines 28 were unable to catalyze Michael
reaction between ketones and nitroalkenes, we found that the
corresponding amino analogs 46, obtained by catalytic hyd-
rogenation of their nitro precursors 28, catalyzed very effi-
ciently this reaction.[26] As it is shown in Scheme 11, organocat-
alyst exo-46 generates Michael adducts (2R,1′S)-47 with good
to excellent ee's. In contrast, diastereomer endo-46 gives rise
to (2S,1′R)-47aa enantiomer, similar to that produced by L-Pro,
with somewhat lower ee. Therefore, we found that a single
transformation of the nitro group to the corresponding amino
derivative results in a transformation of the organocatalytic abil-
ity of the unnatural proline scaffold. Other transformations on
adducts 28[26] permitted to conclude that the exocyclic primary
amino group in (3+2) cycloadducts 46 is essential for catalysis.
DFT calculations[26] on the most relevant transition structures
involved in these Michael additions reproduced correctly the
trends in enantioselectivity found in the experimental studies.
The shape of the transition structures associated with the be-
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Figure 7. (A) Proposed catalytic cycle for the new reaction described in
Scheme 9. Free activation energies calculated for the key steps of the 33b +
26a + 36a → 37a reaction, computed at the B3LYP-D3(PCM = cyclohex-
anone)/6-311+G*//B3LYP-D3/6-31G(d) level of theory, are also given. (B, C)
Optimized structures for TS4b (B) and TS5b (C). Bond lengths are given in
Å. This Figure was adapted from ref.[24]
havior of exo-47 and endo-47 showed that the enamine de-
rived from the primary amino group must adopt axial and iso-
clinal dispositions in (R,1′S)-exo-TS6 and (S,1′R)-endo-TS6, re-
spectively (Figure 8). We found that the stereocontrol is deter-
mined by the antiperiplanar conformation of the aryl substitu-
ent of the nitroalkene, by the optimal angle of attack associated
with the formation of the new C–C bond and by the hydrogen
bonding array between the organocatalyst and the nitro group
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Scheme 10. Synthesis of (+)-pancracine initiated by the three-component re-
action between ketone 33f and nitroalkene 26h promoted by organocatalyst
exo-28aa. The origins of the scaffolds stemming from reactants 33f and 26h
are highlighted in red and blue, respectively.
Scheme 11. Michael addition of cyclic ketones 33 on nitroalkenes 26 in the
presence of organocatalysts exo-46 and endo-46.
of the Michael acceptor. Actually, chemical transformations that
eliminated these hydrogen bonds, for instance via N-acylation
or N-methylation, resulted in inactive pyrrolidine derivatives, as
predicted by the computational studies.
The distinct organocatalytic behavior of catalysts 28 and 46
permitted to perform selective aldol and Michael additions.[26]
Thus, reaction of double electrophile 48 with cyclohexanone
33a in the presence of exo-28aa yielded aldol 49 as the major
isomer with good diastereo- and enantiocontrol. Subsequent
reaction of this latter compound with cyclohexanone in the
presence of exo-46 gave rise to compound anti-50 as the major
diastereomer (Scheme 12). It Is interesting to note that the
Michael addition took place with total diastereo- and enantio-
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Figure 8. Optimized structures [M06–2X/6-31+G(d,p)//B3LYP/6-31G(d) level of
theory] of transition structures (2R,1′S)-exo-TS6 and (2S,1′R)-endo-TS6 lead-
ing to Michael adducts (2R,1′S)-47aa and (2S,1′R)-47aa, respectively. Num-
bers in parentheses correspond to the relative energies (in kcal/mol) of the
transition structures leading to the respective stereoisomers. Bond lengths
are given in Å and deg, respectively. Cartesian coordinates were taken from
ref.[23].
control. However, a partial epimerization of the aldol moiety
occurred and syn-50 was obtained as a minor stereoisomer. In
any case, this example indicates that unnatural organocatalysts
can be used to achieve chemoselective transformations.
Scheme 12. Selective aldol and Michael additions on double electrophile 48
catalyzed by unnatural prolines exo-28aa and exo-46, respectively. PNBA:
para-nitrobenzoic acid.
Highly substituted prolines formed from (3+2) cycloadditions
can be used in selective polymerization reactions.[27] Using cat-
alysts endo- and exo-52, it was found that N-methylated unnat-
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ural proline exo-L-52 is able to catalyze the selective polymeriza-
tion of L-lactide 51 in a racemic mixture of 51. In contrast, endo-
L-52 promoted the enantioselective polymerization of D-lactide
51. In both cases, excellent stereoregularities (see the Pm and
[α] values in Scheme 13) were observed, as well as molecular
weights that closely tracked the monomer-to-initiator ratio.
Scheme 13. Polymerization of racemic D- and L-lactide 51 in the presence of
DBU and organocatalysts endo-52 and exo-52. Benzyl alcohol was used as
initiator. Mn: molecular weight. Pm: probability of meso linkage between
monomeric units.
Also in this case, DFT calculations[27] permitted to explain
the origins of this exceptional stereocontrol. The conforma-
tional flexibility of organocatalysts 52 allows different interac-
tion patterns with the electrophilic and nucleophilic partners
of the polymerization process (Figure 9). In this ring-opening
polymerization (ROP) process, organocatalysis is not covalent
and consists of LUMO activation of the lactide by means of
its interaction with the carboxylic acid, together with HOMO
activation of the nucleophilic alcohol, which is benzyl alcohol
in the first catalytic cycle (methanol in our computational
model), or terminal alkoxy groups of the growing chain during
the polymerization process. This latter activation takes place by
means of the interaction of the hydroxy group with the amino
group of the organocatalyst. When exo-52 catalyzes the ROP
the double carboxy/methylamine interaction takes place via
transition structure (S,S)-exo-TS7, in which the N-methyl group
occupies an equatorial position and is anti with respect to the
carboxy group. In contrast, in the case of endo-52 these groups
are syn to each other, which results in an axial disposition of
the N-methyl group (Figure 9). These preferred interactions,
aside the maximization of the equatorial groups of the catalysts,
account for the selectivity of exo-52 for L-53 via preferred for-
mation of first intermediate ester L-54 and subsequent incorpo-
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ration of additional equivalents of (S,S)-51 (L-lactide). Similarly,
these calculations resulted to be compatible with the selectivity
of endo-52 towards the ROP of (R,R)-51 (D-lactide) to yield
highly stereoregular polymer D-53, although with slightly lower
stereocontrol.
Figure 9. Optimized geometries [B3LYP/6-31G(d) level of theory] of preferred
transition structures (R,R)-endo-TS7 and (S,S)-exo-TS7 associated with the in-
teraction between methanol (as a model primary alcohol) and lactides (R,R)-
51 and (S,S)-51 in the presence of endo-52 and exo-52 (endo,syn-TS). Distan-
ces are given in Å. Data taken from ref.[27].
Chiral dipolarophiles can be used for the synthesis of enan-
tiopure pyrrolidines than in turn are suitable organocatalysts.
Sarotti, Suarez et al.[28] described the stereocontrolled synthesis
of unnatural tricyclic proline derivatives by means of the (3+2)
cycloaddition between imines 56 and levoglucosenone 55 to
yield L-cycloadducts 57 via intermediate N-Ag azomethine yl-
ides. These compounds isomerized under microwave irradiation
to yield the thermodynamically more stable unnatural tricyclic
L-proline esters 58 (Scheme 14).
Scheme 14. Synthesis of tricyclic unnatural L-proline esters 58 via (3+2) cyclo-
addition between levoglucosenone 55 and imines 56.
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Tricyclic unnatural L-proline esters 58 resulted to be efficient
organocatalysts of Diels–Alder (DA) reactions between cyclo-
pentadiene 59 and α,-unsaturated aldehydes such as cinnam-
aldehyde 60. For instance, 58a promoted the formation of
norbonenes 61 with moderate exo-selectivity and ee's
(Scheme 15). Intensive computational analysis of the DA reac-
tions led to Sarotti et al.[29] to predict that organocatalyst 58g
should be more efficient in terms of enantiocontrol. This predic-
tion was successfully corroborated by the experiment
(Scheme 15).
Scheme 15. Diels–Alder reaction between cyclopentadiene 59 and cinnam-
aldehyde 60 catalysed by (3+2) L-cycloadducts 58a and 58g.
In summary, the examples shown in this section demon-
strate that densely substituted unnatural proline derivatives
possess interesting covalent organocatalytic properties medi-
ated by enamine intermediates. These unusual properties range
from the reverse enantiocontrol induced from distal configura-
tions with respect to the active sites, to different scopes by
simple change of functional groups, including the ability to cat-
alyze an unexpected complex three-component cyclization re-
action. In addition, the above discussed example of enantio-
selective polymerization permits to expect further develop-
ments in non-covalent organocatalysis induced by this kind of
synthetic organocatalysts.
3. Unnatural Synthetic Prolines as
Biologically Active Compounds
Pyrrolidines are considered privileged structures in medicinal
chemistry.[30] According to the definition proposed by Evans,[31]
these saturated heterocycles are capable of providing useful
ligands for more than one receptor. Therefore, “judicious modi-
fications of such structures could be a viable alternative in the
search for new receptor agonists and antagonists”.[31] More re-
cently, an analysis of privileged structures based on Shannon
entropy formalism[32] suggests that “heterocyclic, sp3-rich
frameworks are particularly suited for target-focused library de-
sign.” Actually, an analysis of the structural diversity and substi-
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tution patterns of nitrogen heterocycles among U.S. FDA ap-
proved pharmaceuticals[33] revealed that the pyrrolidine ring is
the fifth heterocycle present in approved drugs. Among the 37
pyrrolidine-containing pharmaceuticals, eight of them incorpo-
rate the proline scaffold, with 1–3 additional substituents
(Scheme 16). All these compounds are angiotensin converting
enzyme (ACE) inhibitors,[34] with the exception of Clindamycin,
an antibiotic for the treatment of several bacterial infec-
tions.[35]
Scheme 16. U.S. FDA approved pharmaceuticals containing proline scaffolds.
The above indicated pharmaceuticals can be obtained by
derivatization of L-proline or other post-translational proline de-
rivatives. Therefore, as far as the chemical synthesis of highly
prescribed drugs is concerned, to date (3+2) cycloadditions
have been used for the synthesis of other aromatic five-mem-
bered nitrogen containing pharmaceuticals[36] such as cele-
coxib.[37] One patented synthesis of prescription drug atorvas-
tatin[38] is an exception to this statement (vide infra). In the
following sections the synthesis of biologically active substi-
tuted prolines or their aromatized 1H-pyrrole derivatives is pre-
sented. Although these compounds are not in clinical use so
far, most likely the role of these compounds (or their analogs)
in Medicinal chemistry will be more relevant in the years to
come.
3.1. Synthesis of Biologically Active Racemic Prolines via
(3+2) Cycloadditions
Racemic proline derivatives are useful intermediates in the syn-
thesis of pharmaceuticals when aromatization processes occur
during or after the (3+2) cycloaddition to yield substituted 1H-
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pyrroles. A relevant example consists of the (3+2) cycloaddition/
(4+2) cycloreversion of azomethine ylide 63 (derived from
amino acid 62) with alkyne 64 to yield cycloadduct 65 that in
situ decarboxylates to yield pentasubstituted 1H-pyrrole 66,[38]
a key precursor of atorvastatin (Scheme 17), a prescription drug
used to lower blood cholesterol.
Scheme 17. Synthesis of atorvastatin by (3+2) cycloaddition between azo-
methine ylide 63 and alkyne 64.
Another example of synthesis of biologically active 1H-pyrr-
oles by aromatization of pyrrolidines is the synthesis of histone
deacetylase (HDAC) inhibitors via (3+2) cycloaddition between
imines 27 and nitroalkenes 26.[39] Under thermal conditions,
mixtures of endo- and exo-cycloadducts 67 were formed, whose
aromatization under thermal heating or microwave irradia-
tion[8a] gave mixtures of methyl 3,5-diaryl-1H-pyrrole-2-carbox-
ylates 68 and 69. Subsequent functionalization of these
latter aromatic cycloadducts led to hydroxamic acids 70,
which in some cases such as of compound 70a, resulted to be
very potent HDAC inhibitors, with IC50 values within the picom-
olar range[40] (Scheme 18). This latter molecule has shown
strong growth-inhibitory effect in Burkitt's cell lymphoma, follic-
ular lymphoma and, especially, mantle cell lymphoma
(MCL).[40b]
Racemic dispiropyrrolidines constitute potentially useful anti-
inflammatory agents.[41] Reaction of isatins 71 with sarcosine
20 led to the formation of fleeting azomethine ylides 72, whose
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Scheme 18. Synthesis of HDAC inhibitors via consecutive (3+2) cycloaddition/
aromatization reactions.
reaction with dipolarophile 73 yielded racemic tricyclic dispiro-
pyrrolidines 74 in good yields (Scheme 19). These racemic com-
pounds showed interesting in vivo anti-inflammatory activity,
measured as aedema inhibition.
Scheme 19. Synthesis of anti-inflammatory racemic dispiropyrrolidines (±)-74
by reaction of isatins 71a,b with sarcosin 20. Potencies were measured with
respect to reference standard indometracin.
A similar approach was followed to synthesize inhibitors of
advanced glycation end product, which is a relevant target in
the treatment of diabetes mellitus.[42] Reaction of isatin 71a
with benzylamine led to highly substituted racemic spiro-
prolines 77 with excellent diastereocontrol and chemical yields
via reaction of azomethine ylide 75 with α,-unsaturated ket-
ones 76. (Scheme 20) .
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Scheme 20. Synthesis of inhibitors of advanced glycation end products by
(3+2) cycloaddition between azomethine ylide 75 and α,-unsaturated ket-
ones 76.
3.2. Synthesis of Biologically Active Prolines via
Asymmetric Catalysis on (3+2) Cycloadditions
Nájera and Sansano[43] have demonstrated the usefulness of
1,3-dipolar reactions with N-metallated azomethine ylides for
the synthesis of drug candidates for hepatitis C treatment. Reac-
tion of tert-butyl acrylate 78 with imines 29i,j led to substituted
L-prolines 81a,b with high chemical yield and diastereo- and
enantiocontrol in the presence of chiral ligands 79[44] and 80[45]
and using AgI and AuI metallic salts, respectively (Scheme 21).
N-Acylation and deprotection of both ester groups led to the
inhibitors of hepatitis C virus 82a,b in good overall yields and
excellent enantioselectivities.
Using (R)-Fesulphos 83 as chiral ligand, Antonchick and
Waldmann[46] described the enantioselective synthesis of
iridoid-inspired bicyclic proline derivatives (Scheme 22) by
means of a (3+2) cycloaddition between imines 27 and racemic
2H-pyran-3(6H)-one derivatives 84. Under the reaction condi-
tions gathered in Scheme 22, the authors obtained bicyclic
(3+2) cycloadducts with good yields and stereoselectivities. In
all the reported examples, endo diastereomers were obtained
with diastereomeric excesses of ca. 90 % and ee's up to 96 %,
L-proline configuration being the major one. Since only the (S)-
enantiomer of dipolarophiles 84 was able to react with the cor-
responding imine 27, the method provides a kinetic resolution
of racemic 2H-pyran 3(6H)-ones 84. Among the 28 cycloadducts
thus synthesized, five of them showed promising inhibitory ac-
tivity of the Hedgehog (Hh) and Wingless/integration (Wnt) sig-
naling pathways (Scheme 22).[46]
The same research group[47] reported the synthesis of func-
tionalized tropanes by means of (3+2) cycloaddition between
nitroalkenes 86 and azomethine ylides derived from tryptophan
derivatives 87 (Scheme 23). Using CuI as source of the N-metal-
lated azomethine ylide and (R)-Fesulphos 83 as chiral ligand,
the authors obtained tetracyclic proline esters 88 in good yields
and excellent ee's. In this case, exo cycloadducts were obtained.
The structure of amino esters 88 is closely related to that of
tropanes, whose biological activity in naturally occurring com-
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Scheme 21. Asymmetric synthesis of hepatitis C virus polymerase inhibitors
82a,b from imines 29i,j.
Scheme 22. Synthesis of Hedgehog (Hh) and Wingless/integration (Wnt) sig-
naling pathways inhibitors 85 from 2H-pyran-3(6H)-one dipolarophiles 84
and imines 27.
pounds is well known. The authors prepared 22 (3+2) cycload-
ducts 88. In three cases, significant Hh activity was observed
(Scheme 23). Interestingly, the chiral configuration of these
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(3+2) cycloadducts was found to be relevant for biological ac-
tivity, since in the case of racemic 88a no Hh inhibitory activity
was observed.[47]
Scheme 23. Synthesis of Hedgehog (Hh) signaling pathway inhibitors 88 from
nitroalkenes 86 and tryptophan-derived imines 87.
3.3. Synthesis of Biologically Active Prolines via (3+2)
Cycloadditions Involving Enantiopure Dipolarophiles
1,3-Dipolar reactions between azomethine ylides usually re-
quire π-deficient alkenes incorporating electron-withdrawing
groups such as carboxamido, ester or nitro groups. A relevant
example of dipolarophiles incorporating chiral esters consists
of the reaction between azomethine ylide 90 and enantiopure
alkene 89 to yield tricyclic (3+2) adduct 91. Treatment of this
latter compound with AgOTf led to 3,4-dihydro-2H-pyrrole 92
together with two additional diastereomers in a diastereomeric
excess of 66 %. Compound 92 was converted to (2S,4R)-93
(Scheme 24). This proline derivative proved to be a potent in-
Scheme 24. Synthesis of glutamate transport inhibitors 93 by reaction be-
tween azomethine ylide 90 and chiral alkene 89.
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hibitor of CNS L-glutamate neurotransmitter transporters. Inter-
estingly, (2S,4R)-93 showed non-substrate inhibitory activity, in
contrast with the biological behavior observed for its non-
methylated analogue.[48]
Nájera, Sansano et al.[49] used acrylates derived from (R) and
(S)-lactate to synthesize hepatitis C inhibitors 82 (Scheme 25).
Reaction between imine 29i and (R)-acrylate 94 [prepared from
acrylic acid and methyl (R)-lactate] in the presence of silver
acetate yielded unnatural L-proline 95 with excellent diastereo-
meric excess. Subsequent derivatization of this latter cycload-
duct permitted to obtain compound 82a with high yield and
enantiocontrol. A similar route starting from (S)-lactic acid led
to ent-82b.
Scheme 25. Synthesis of hepatitis C virus inhibitor 82a from chiral acrylate
94.
The 1,3-dipolar reaction between azomethine ylides and α,-
unsaturated carbonyl compounds can be extended to intra-
molecular processes that actually involve a common chiral pre-
cursor. For instance, in situ formation of azomethine ylides 97
(Scheme 26) from amine 96 led to a tricyclic cycloadduct 98.[50]
Scheme 26. Synthesis of an analogue of antibacterial agent cethromycin 99
by intramolecular (3+2) cycloaddition of azomethine ylide 97.
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Compound 99, which incorporates a highly substituted poly-
cyclic L-proline scaffold, is a cyclic analogue of antibacterial
agent cethromycin and was obtained from 98 after a deprotec-
tion/oxidation sequence.
Enantiopure nitroalkenes can also be used for the synthesis
of biologically active compounds. We prepared chiral nitroalk-
enes 100 from L-Leu and L-Ile (Scheme 27). These latter di-
polarophiles reacted with N-Ag azomethine ylides derived from
imines 29 to yield, after a (3+2) cycloaddition/ester hydrolysis
sequence, L-prolines 101 with excellent endo diastereocon-
trol.[51] Subsequent amide coupling with linear amino esters
and hydrolysis led to compounds 103. When the coupling reac-
tions were carried out with glycine methyl ester (n = 0), the
corresponding adducts showed excellent inhibitory activity of
Very Late Antigen-4 (VLA-4), an α41 integrin involved in
murine models of hepatic melanoma metastasis.[51] On the
other hand, when n = 1,4 adducts 103 showed excellent antag-
onists ability of Leucocyte Function Associated Antigen-1 (LFA-
1) αL2 integrin,[52] which is involved in early and late stages of
cancer development. Alternatively, N-acylation of compounds
102 followed by deprotection of the phthalimido group yielded
compounds 105, which also showed LFA-1 antagonist activity
in a murine model of colon cancer[52] (Scheme 27).
Scheme 27. Synthesis of VLA-4 and LFA-1 integrin inhibitors 103 and 105 via
(3+2) cycloadditions involving enantiopure nitroalkenes 100.
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3.4. Synthesis of Biologically Active Prolines via (3+2)
Cycloadditions Involving Enantiopure Azomethine Ylides
In Section 2.1, we have shown that NH-D-EhuPhos 25 can react
with imines 27c–e and 31a–c to yield syn- and anti-γ-nitro-α-
amino esters 32 by an interrupted stepwise 1,3-dipolar reaction
that stops at the Michael addition step.[20] From these amino
esters we generated cis- and trans-γ-lactams 106 after a cata-
lytic hydrogenation/imine formation sequence (Scheme 28). In
situ formation of the N-Ag azomethine ylides 107 and reaction
with suitable dipolarophiles yielded spiro-L-proline derivatives
108 with excellent endo stereocontrol. It is noteworthy that the
chiral information of α-carbon atoms of γ-lactams 106 is lost
after formation of the corresponding azomethine ylides. There-
fore, the chirality of the C atom of the 1,3-dipoles is the only
responsible for the formation of one given enantiomer of (3+2)
cycloadducts 108, which incorporate up to four additional chi-
ral centers.
Scheme 28. Formation of spiro-L-prolines 108 from γ-nitro-α-amino esters 32.
Some of these spiro-L-proline lactams showed interesting
biological activity.[20] For example, spiro compound 108 with
R1 = R2 = Ph and EWG-R3 = N-methyl phthalimido is an inhibitor
of proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme
with IC50 = 5 μM. In addition, conversion of tert-butyl ester 108a
into acid 109, followed by N-acylation, deprotection of the
methyl ester and N-hydroxyamidation led to hydroxamic acid
110 with good yield (Scheme 29). This latter compound showed
antiproliferative activity in HeLa nuclear extracts via HDAC inhi-
bition.[20]
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Scheme 29. Synthesis of HDAC inhibitor 110 from spiro-L-proline derivative
108a.
4. Conclusions and Outlook
The pyrrolidine ring present in L-Pro represents a good compro-
mise between preorganization and a certain conformational
flexibility. Highly substituted unnatural proline derivatives allow
for the incorporation of chirality sources and additional func-
tional groups. These features confer convenient properties
upon densely substituted unnatural proline scaffolds. Fortu-
nately, (3+2) cycloaddition between azomethine ylides and π-
deficient alkenes is a powerful chemical tool to generate the
pyrrolidine ring in a highly regio-, diastereo- and enantiocon-
trolled manner. This stereochemical control can be achieved by
using enantiopure reactants and by means of asymmetric catal-
ysis.
The (3+2) cycloaddition between enantiopure ferrocenyl
imines and nitroalkenes leads to the synthesis of chiral EhuPhos
ligands, in which the interplay between planar and central
chiralities results in highly efficient and selective P-, P,O- and
P,N-ligands. These ligands can be used as chiral catalysts in
other chemical transformations, including asymmetric (3+2)
cycloaddition between similar reactants, to generate an off-
spring of unnatural L-proline derivatives.
These latter cycloadducts are excellent organocatalysts (off-
spring catalysts) in different reactions that include aldol and
Michael additions, as well as enantioselective ring opening po-
lymerizations. In one case, an unexpected three-component re-
action has been observed. The behavior of these unnatural
L-prolines is different to that observed for organocatalysts de-
rived from the natural amino acid. In particular, the origins of
the stereocontrol are related to the chirality of the distal substit-
uents with respect to the active site. Thus, endo and exo cyclo-
adducts show different stereochemical outcomes. The possibili-
ties of this kind of organocatalysts in both enamine (HOMO
raising) and non-covalent (LUMO lowering) catalysis remain
largely unexplored.
The above-mentioned tradeoff between preorganization and
flexibility present in the sp3-rich pyrrolidine ring can be useful
in the chemical synthesis of novel biologically active unnatural
proline derivatives. A relatively reduced number of molecules
of this kind of compounds has been reported so far. However,
we are convinced that the favorable features of the (3+2) cyclo-
Eur. J. Org. Chem. 2018, 5889–5904 www.eurjoc.org © 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5903
addition between azomethine ylides and alkenes will be in-
creasingly used in the synthesis of proline derivatives as privi-
leged structures for drug discovery.
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